Freeline Therapeutics Holdings plc (Nasdaq: FRLN), relating to its proposed sale to Sycona Ltd. Under the terms of the agreement, FRLN shareholders will receive $6.50 in cash per share they own.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN), relating to its proposed sale to Sycona Ltd. Under the terms of the agreement, FRLN shareholders will receive $6.50 in cash per share they own.